[Live Podcast] Incentivizing Drug Development: Patents or Prizes?
January 13, 2021 at 12:00 PM ET
Medical innovation has made modern life miraculous by historical standards, as demonstrated by the unprecedented medical response to the COVID-19 pandemic. What made this possible? What’s the best way to ensure future innovation in the treatment of viruses like COVID-19, and of other diseases like hepatitis, diabetes, and cancer?
This live podcast will explore the legal rules and institutions best-suited to promote the development and commercialization of new drugs and vaccines. One key question is whether to use a prize or patent system to incentivize drug development. Another is whether consumers pay twice for patented drugs developed using funding from the National Institutes of Health. Experts will debate these questions and discuss the the legal, economic, and policy considerations at play for efforts to promote new medical innovation.
- Deep Dive Episode 118 – Can Patents and Bayh-Dole Fuel Innovation in the Time of COVID-19?
- How Antitrust Overreach is Threatening Healthcare Innovation
- With biomedical research, taxpayers are getting a great deal
- Overcharged: Why Americans Pay Too Much for Healthcare
- Are We ‘Paying Twice’ for Pharmaceuticals?
- Trump’s move to cut drug prices will crush U.S. innovation
Scott K. Ginsburg Professor of Health Law & Policy
Partner, Dinsmore & Shohl LLP and
Past President, Licensing Executives Society, USA & Canada
Professor of Law
Antonin Scalia Law School, George Mason University